The incidence rate of allergic reactions induced by oxaliplatin is higher in patients with rectal cancer compared with colon cancer

Abstract

Aim

To explore the diverse profiles of adverse reactions caused by oxaliplatin between colon and rectal cancer, we investigated the toxicity of oxaliplatin in patients with colon and rectal cancer.

Methods

From January 2017 to December 2021, 200 cases of sporadic CRC patients with adverse reactions after oxaliplatin were collected from Harbin Medical University Cancer Hospital, Harbin, China. All patients received a chemotherapy regimen containing oxaliplatin (100 colon cancer and 100 rectal cancer). We reviewed the adverse reactions induced by oxaliplatin in patients with colon and rectal cancer.

Results

We found there was no significant difference in gastrointestinal toxicity, hematotoxicity, neurotoxicity, hepatotoxicity, respiratory toxicity, and cardiotoxicity caused by oxaliplatin between patients with colon cancer and patients with rectal cancer, but patients with rectal cancer were more prone to allergic reactions than patients with colon cancer after oxaliplatin. In addition, we found neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratios (PLR) were higher in patients with colon cancer than in patients with rectal cancer. This may reflect differences in immune status and inflammatory responses between colon cancer and rectal cancer, which might be the reason for more allergic reactions caused by oxaliplatin in colon cancer patients compared to rectal cancer patients.

Conclusion

Except for a higher incidence of allergic reactions in patients with rectal cancer, no significant difference in the incidence of adverse drug reactions associated with oxaliplatin was noted between patients with colon cancer and rectal cancer. Our results suggested more attention should be paid to the allergic reaction caused by oxaliplatin in patients with colon cancer.

Keywords:

• Colon cancer
• rectal cancer
• oxaliplatin
• adverse reactions
• allergic reactions

Ethical statement

Ethical approval was waived by the local Ethics Committee of Harbin Medical University Cancer Hospital in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

Author contributions

Tong Liu: Drafting the manuscript

Yao Jin: Data analysis

Xu Yang: Data analysis

Zhiqiang Tong: Data analysis

Mei Dong: Design of this study

Patient consent

Informed consent was obtained from all individual participants included in the study.

Consent to publish

The participant has consented to the submission of the report to the journal.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

All data generated or analyzed during this study are included in this published article.

Additional information

Funding

This study was supported by the Haiyan Foundation of Harbin Medical University Cancer Hospital (JJQN2023-09), Project of Beijing Medical Award Foundation (YXJL-2022-0187-0013), Beijing Hongdingxiang Public Welfare Development Center (BJ-HDX-20220437).